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Abstract 
Molecular imaging has undergone an explosive advancement in recent years, due to the 
tremendous research efforts made to understand and visualize biological processes. Molec-
ular imaging by definition assesses cellular and molecular processes in living subjects, with the 
targets of following metabolic, genomic, and proteomic events. Furthermore, reporter gene 
imaging plays a central role in this field. Many different approaches have been used to visualize 
genetic events in living subjects, such as, optical, radionuclide, and magnetic resonance im-
aging. Compared with the other techniques, magnetic resonance (MR)-based reporter gene 
imaging has not occupied center stage, despite its superior three-dimensional depictions of 
anatomical details. In this article, the authors review the principles and applications of various 
types of MR reporter gene imaging technologies and discuss their advantages and disad-
vantages. 
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Principles of molecular magnetic resonance 
imaging 
The major goal of molecular imaging is the spa-
tiotemporal  imaging  of  genomic  and  proteomic 
events. Molecular imaging encompasses the fields of 
chemistry, biology, physics, and medicine, and brings 
experts in these scientific fields together to determine 
means of visualizing molecular and cellular events [1, 
2] 
Molecular  imaging  includes  several  imaging 
modalities,  such  as,  bioluminescence,  fluorescence, 
positron emission tomography (PET), single photon 
emission computed tomography (SPECT), computed 
tomography  (CT),  optical  imaging,  ultrasound,  and 
magnetic resonance imaging (MRI). The advantages 
and  disadvantages  of  these  modalities  have  been 
discussed extensively in the literature [1]. MRI is well 
known for its superior three-dimensional resolution, 
and  can  be  used  to  acquire  physiological  and  ul-
tra-fine anatomical information using different pulse 
sequences.  Unlike  other  cross-sectional  modalities, 
such as, PET, SPECT, and CT, MRI is free from the 
issue  of  ionizing  radiation  with  arbitrary  imaging 
planes and provides multiplanar imaging capabilities. 
Ultrasound and optical imaging are limited in their 
ability to detect signals through deep tissue. CT pro-
vides anatomical maps for PET/SPECT; however, its 
role in molecular imaging is restricted due to its low 
sensitivity and limited contrast resolution of soft tis-
sue. One of the biggest advantages of MRI is its ability 
to provide images of deep tissues in a background of 
superb  anatomical  detail.  Furthermore  like  CT  and 
ultrasound, MR scanners are widely available that can 
accommodate large animals.  
The disadvantages of MRI are difficult interpre-
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tation  among  complex  background  signal  intensity 
and its relatively low sensitivity. According to Mas-
soud et al, the sensitivity of MRI probe detection is 
106-109 times lower than PET and 1010-1014times lower 
than  bioluminescence.  However,  thanks  to  the  de-
velopment of high field MRI and improved hardware 
and software designs, the signal to noise ratio of MRI 
has  been  improved  significantly  [1],  and  novel  ap-
proaches used for reporter gene imaging may further 
increase its sensitivity and specificity.  
In  a  typical  MRI,  the  signal  provided  by  the 
smallest image element is a function of mobile proton 
in hydrogen molecule and the relaxation time. There 
are  two  types  of  relaxation  times,  that  is,  a  T1 
spin-lattice relaxation time, and a T2 spin-spin relaxa-
tion time. Different pulse sequences exploit localized 
variations  in these  relaxation times, so that a given 
element (a voxel) takes on different signal intensities 
according  to  physiological  conditions.  “Enhance-
ment” is used to increase voxel contrast by perturbing 
the  local  environment.  Gadolinium,  the  most  com-
monly  used  MR  contrast  “enhancement”  material, 
shortens T1 and produces bright voxels correspond-
ing to gadolinium-containing region on T1-weighted 
images.  On  the  other  hand,  iron,  the  second  most 
common  contrast  agent,  shortens  T2,  and  produces 
dark  voxels  on  T2-weighted  images.  T1-shortening 
agents  are  more  useful  clinically  because  target  le-
sions are imaged at high signal-to-background ratios, 
whereas T2-shortening agents have higher sensitivity 
at the molecular level [3] . 
Two types of labeling mechanisms can be used 
to target a biological process or a cell using MRI. Di-
rect labeling involves the binding of gadolinium or an 
iron-containing compound to the cell surface or in-
ternalized  intracellularly.  The  other  mechanism  in-
volves reporter gene techniques that induce specific 
genetic cascades. The major benefits of reporter gene 
techniques are that cells must be viable to produce an 
imaging signal, and that imaging signal does not di-
lute with cell division [4]. Research is being under-
taken  to  find  safe  transgene  strategies  for  reporter 
gene imaging. 
The mechanism of MR reporter gene imaging 
Reporter gene imaging by MRI can be grouped 
into  four  types:  enzyme-based,  spectroscopy-based, 
iron-related, or chemical exchange saturation transfer 
(CEST)-based.  
Enzyme-based Studies 
Enzyme-based MR can be divided into two mo-
dalities, one for MR spectroscopy (MRS) and the other 
for MR imaging (MRI).  
Several approaches to enzyme-based MRI have 
been devised. One pioneering example involved the 
use of ß-galactosidase (Figure 1). Louie et al. devel-
oped  a  gadolinium-based  substrate  that  contains  a 
galactose group, which conceals the central gadolin-
ium  atom.  In  the  presence  of  galactosidase  (intro-
duced  by  lacZ  transfection),  the  galactopyranose 
moiety is enzymatically cleaved, which allows a water 
molecule to access the gadolinium, and increase the 
T1  signal  [5].  More  recent  study  combined 
lacZ-transfected tumor with 3,4-cyclohexenoesculetin 
b-D-galactopyranoside and ferric ion, which result in 
T2* relaxation on MRI [6].  
 
 
 
Figure  1.  EgadMe.  (A)  Schematic  diagram  representing  the 
site-specific placement of the galactopyranosyl ring on the tet-
ra-azamacrocycle. When galactosidase cleaves the sugar (at the 
red bond), the inner Gd3+ ion becomes more accessible to water. 
(B)  3-dimensional  T1-weighted  MR  image  of  a  living  embryo. 
Plasmid carrying the lacZ gene was injected into one cell at the 
two-cell stage.Subsequent enzyme expression was on the left side 
of the embryo. Regions of high signal intensity were found in the 
endoderm (e), head (h), and ventrally (red arrows). (C) Bright-field 
image  of  an  embryo  fixed  and  stained  with  X-gal.  Regions 
demonstrating enzyme expression correlated with regions of high 
intensity in MR images. [Reprinted from ref. 5 with permission]. Theranostics 2012, 2(4) 
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Figure 2. T1-weighted gradient-echo MR image of cells with or 
without tyrosinase. Image of two cell clones (one clone in each 
column) cultured under conditions that allowed tyrosinase ex-
pression (top row) or did not allow its expression (bottom row). 
After culturing with iron- and holotransferrin-enriched medium, 
cells that were tyrosinase positive showed higher signal intensity 
by  T1WI  imaging  because  of  the  presence  of  metallomelanin. 
[Reprinted from ref. 8 with permission]. 
 
Another example is provided by the tyrosinase 
gene  (Figure  2).  Tyrosinase  is  required  for  the  pro-
duction of  melanin,  which binds paramagnetic iron 
ions  to  produce  metallomelanin,  a  T1-shortening 
agent.  Cells  overexpressing  tyrosinase  thus  exhibit 
high signal intensity on T1-weighted images [7, 8].  
Nevertheless,  enzyme-based  MR  reporter  gene 
imaging faces many challenges. One problem associ-
ated with the ß-gal-based approach is that even when 
the enzyme has not cleaved off galactose, outer sur-
face relaxation changes of the gadolinium-containing 
compound are  non-zero. Thus, while one might as-
sume  that  the  background  signal  would  be  zero 
without  any  endogenous  ß-galactosidase,  some  en-
hancement  may  actually  occur  in  practice.  Another 
problematic issue concerns the delivery barrier, which 
restricts substrate access to the transfected cell. In ad-
dition, the persistence of melanin and metallomelanin 
in cells, even when the reporter gene is not activated, 
cause false high MRI signal intensities [9]. 
Spectroscopy-based Studies 
MR  spectroscopy  or  MRS  techniques  take  use 
catalytic enzymes, such as, creatine kinase and argi-
nine kinase, and their conversion of ATP to ADP, us-
ing 31P MR spectroscopy (MRS) [10]. For example, the 
arginine kinase gene from Drosophila can be trans-
fected into vertebrate muscle using a viral vector, and 
the byproduct of the enzymatic conversion of ATP, 
phosphorarginine, can be detected by 31P MRS. The 
expression and activity of the transfected kinase can 
be followed in living mammalian muscle for several 
months  after  injection  [11].  Another  approach  in-
volves the use of a reporter enzyme to follow a pro-
drug during its internalization and conversion by a 
target cell, for example, the cytosine deaminase gene 
catalyzes  the  conversion  of  the  prodrug 
5-fluorocytosine  into  5-fluorouracile  in  tumor  cells, 
which can be monitored by 19F MRS [12]. The fluor-
ouracile  and  fluorocytosine,  being  anions,  cannot 
cross the cell membrane and are retained in the cell, 
therefore serve as a means to develop contrast. Fur-
thermore, the cytosine deaminase result in toxic me-
tabolite formation in the transfected tumor, suggest-
ing that reporter gene technology can provide cancer 
gene therapy in the future [12-14]. 
 
 
 
Figure  3. F19 MR spectra MCF7 breast tumor in mice.  Data 
demonstrating the uptake and metabolism of OFPNPG after direct 
intratumoral injection. The spectra in the upper panel shows the 
data from the lacZ tumor, and the lower panel from the wild type 
tumor. The breakdown of OFPNPG to OFPNP was observed in 
the ß-gal-positive tumor. No conversion was seen in the control. 
[Reprinted from ref. 17 with permission]. 
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Another enzymatic reporter gene technique for 
MRS utilizes b-galactosidase. Here, 19F MRS monitors 
the transformation of a fluorinated version of the tra-
ditional  ß-D-galactopyranoside  (p-fluoro-o- 
nitrophenyl-ß-D-galactopyranoside;  PFONPG,  or  its 
isomer  o-fluoro-p-nitrophenyl-ß–D-galactopyrano-
side: OFPNPG), to aglycone (p-fluoro-o-nitrophenol: 
PFONP), by cells transfected with the lacZ gene. The 
substrate PFONPG may be superior to EgadMe since 
it penetrates the cell membrane to be accessible to the 
intracellular  enzyme,  thus  alleviating  the  delivery 
barrier  issue  and  facilitating  the  in-vivo  translation 
[15-17]. 
The  limitations  of  MRS  are  the  kinase-based 
study relies on energy metabolism, and that its images 
are of relatively low spatial resolution. It remains to 
be seen whether such a reporter gene method can be 
translated  to  multicellular  organisms  or  to  multidi-
mensional imaging [9, 18, 19]. 
Iron-related Reporter Gene Studies 
Recent reports have described iron-binding pro-
teins  other  than  metallomelanin.  Weissleder  et  al. 
used an engineered transferrin receptor (ETR, Figure 
4), which generated contrast by the receptor-mediated 
internalization  of  ironbound  transferrin.  This  tech-
nique  was  used  to  image  ETR-transfected  (ETR+) 
gliosarcoma xenografts in mice after the systemic in-
jection of a receptor-targeted probe, and it was found 
that ETR+ tumors showed significantly lower signal 
intensity  on  T2  gradient-echo  images  than  con-
trol-transfected  (ETR-)  tumors  [20].  However,  the 
overexpression  of  ETR  or  tyrosinase  could  lead  to 
iron-catalyzed free radical formation via the Fenton 
reaction, and be potential toxic to cells [21, 22].  
Ferritin is a ubiquitous protein which stores and 
releases the iron, and is activated by excess free in-
tracellular iron to maintain iron homeostasis. The pi-
oneering work by Cohen et al was based on the hy-
pothesis  that  overexpression  of  ferritin  would  trap 
excess intracellular iron, and provide a signal without 
injection of exogenous contrast agent. It was shown 
that the induced expression of ferritin caused signifi-
cant T2 relaxation time shortening [23]. In a C6 glioma 
xenografts transfected with TET-responsive enhanced 
green  fluorescent  protein  (EGFP)  and  heavy-chain 
transferrin (C6-TET-EGFP-HA-ferritin), the absence of 
tetracycline in drinking water was found to increase 
the spin-spin relaxation rate (Figure 5, 6). It should be 
noted that exogenous iron, such as SPIO (superpara-
magnetic  iron  oxide),  was  not  administered  for  the 
signal detection. Genove et al. described the effect of 
the  injection  of  viral  vector  carrying  ferritin  into 
mouse  brain.  Localized  ferritin  overexpression  was 
found  to  result  in  decreased  T2  time  and  thereby 
generating  MR  contrast  by  increasing  R1  and  R2’ 
(R1=1/T2). It was also found that ferritin-transduced 
cells showed no adverse effect over control cells [24]. 
In fact, various reports, including a review of ferritin 
by Arozio et al, have suggested that ferritin plays key 
roles in the following process: the reduction of reac-
tive oxygen species levels, anti-angiogenesis, and in 
the  reduction  of  cellular  apoptosis  from  oxidative 
stress [25-27].  
 
 
Figure 4. In vivo MR imaging of a mouse engineered transferrin receptor positive (ETR+) (left image) and ETR– (right) tumors. (A) On 
T1-weighted images, ETR– and ETR+ tumors had similar signal intensities. (B) T2-weighted gradient-echo image showing substantial 
differences between ETR– and ETR+ tumors. ETR-mediated cellular accumulation of the Tf-MION probe decreases signal intensity, due 
to an increased transverse relaxation rate (R2) after cellular internalization, which was most pronounced using T2-and T2*-weighted 
sequences. (C) Composite color mapimage of a T1-weighted spin-echo obtained for anatomic detail with superimposed R2 changes after 
probe administration. [Reprinted from ref. 20 with permission]. Theranostics 2012, 2(4) 
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Figure  5.  Schematic  diagram  of  the  expression  of  EGFP-HA-ferritin  for  multimodality  endogenous  reporter  gene  expression. 
C6-TET-EGFP ferritin was generated by infecting C6 cells with virus carrying the TET transactivator (tTA) under a constitutive promoter 
(pRev-tTA-OFF-IN  vector).  Cells  were  then  transfected  to  express  TET-EGFP-HA-ferritin  using  a  bidirectional  vector 
(pBI-EGFP-HA-Ferr vector). Selected clones showing the overexpressions of EGFP and HA-tagged ferritin, both of which were tightly 
suppressed by the administration of TET (+Tet).In the absence of TET (-Tet), ferritin overexpression led to the redistribution of in-
tracellular ferritin iron and the chelation of intracellular free iron, thereby generating MR contrast by increasing R1 (1/T1) and R2. 
[Reprinted from ref. 23 with permission]. 
 
 
 
Figure 6. In vivo MR images of switchable ferritin expression in C6 tumors. R1 and R2maps overlaid on the MR images of ferri-
tin-expressing tumors. After inoculation of C6-TETEGFP-HA-ferritin tumor cells in the hind limb of nude mice, TET and sucrose (or 
sucrose only for control) were supplied in drinking water. (a) The images in the top row show R1 and R2 in a TET+ status, and the bottom 
row R1 and R2 in a TET- status. [Reprinted from ref. 23 with permission]. 
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Questions regarding anomalies of ferritin-related 
relaxation remain to be answered. The phenomenon 
of T2-weighted image darkening by iron near protons 
is  well  known,  but  the  measurements  of  relaxation 
rates  and  of  iron  quantities  are  sensitive  to  experi-
mental protocols and researchers, for example, they 
are  affected  by  different  tissues,  different  solutions, 
molecular  aggregation,  MR  field  strength,  and  the 
quantification method used [28]. One unique feature 
of MRI is the linear relationship between R2 and the 
external  magnetic  field;  although  a  quadratic  rela-
tionship has been suggested [29, 30]. For example, the 
relaxation rate induced by deoxyhemoglobin, another 
iron-associated  protein,  shows  a  quadratic  increase 
with respect to R2. To complicate the story further, the 
relaxation of iron, normalized by iron concentration, 
has different values in different tissues and even in 
the  same  tissues  from  different  researchers.  These 
variances suggest that relaxation is not caused by iron 
but  rather  by  ferritin  and  hemosiderin.  It  has  been 
suggested that differently sized aggregations of ferri-
tin  in  tissues  explain  these  discrepancies  [28,  31]. 
Furthermore, the signal change induced by ferritin is 
dependent on the redistribution of intracellular iron, 
rather than on net iron content [23]. These confound-
ing factors suggest that the main drawback of ferritin 
reporter gene imaging is its semiquantitative nature 
[30]. More recently, Choi et al suggested using the R50 
values than the T2* values themselves for in vivo iron 
quantification [32]. By using melanoma cell line which 
stably expresses ferritin (myc-hFTH), they were able 
to  evaluate  the  tumor  burden  in  metastatic  lymph 
node (Figure 7). The drop in T2* value was noted in 
the  myc-hFTH  cells,  but  the  histogram  overlapped 
with those of control cells, making it difficult to draw 
a  threshold  for  tumor  burden.  The  cumulative  T2* 
histogram  analysis  and  its  representative  median 
value, R50, and may hold promise in future studies. 
 
Figure 7. In vivo imaging and histological analysis of metastatic cells expressing myc-tagged human ferritin heavy chain (myc-hFTH) in 
lymph nodes (LNs). (A) T2* map and histograms of metastasis from myc-hFTH (right image) and control cells (left image) in the right and 
left axillary (A) and brachial (B) LNs in nude mice, respectively. The ferritin-carrying lymph node (white arrows in right) metastasis shows 
left-shift of the T2* histogram (right top and bottom) compared with the control (left top and bottom). [Reprinted from ref. 32 with 
permission].  Theranostics 2012, 2(4) 
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Recently,  the  MagA  gene,  which  synthesizes 
magnetosomes  in  some  bacteria,  has  attracted  re-
search attention. The gene product has properties in 
common with SPIO nanoparticles. In a study by Zu-
kiya et al., the T2*-weighted images of magA-positive 
cells  showed  significant  signal  drops  as  compared 
with  those  of  control  cells.  Electron  microscopy  re-
vealed  uniform  particles  magnetosomes.  Cytosolic 
G6PD and MTT assays did not show cytotoxicity or 
change in cell proliferation. Particles produced in the 
magA-transfected animal cell do not cause  immune 
response  trigger  on  cell  surfaces  (Figure  8,  9).  Ac-
cordingly,  it  has  been  suggested  that  magA-based 
imaging  may  provide  a  new  means  of  noninvasive 
cellular tracking [33]. 
Chemical Exchange Saturation Transfer 
The newest class of MR contrast agents utilize a 
process called chemical-exchange saturation transfer 
(CEST). Here, frequency-selective irradiation, or sat-
uration is used to label protons noninvasively in ly-
sine-rich  protein  (LRP).  The  spin  saturation  is  then 
transferred  to  bulk  water  resonance,  and  thus, 
changes the signal intensity of the water and provides 
on  and  off  contrast.  Gilad  et  al.  transfected 
LRP-encoding  mammalian  vector  into  glioma  cells, 
which  were  then  inoculated  into  murine  brains. 
LRP-expressing cells were selective saturated at the 
exchangeable  proton-resonance  frequency,  and  the 
signal intensity–difference map obtained was found 
to differentiate between LRP-expressing tumors and 
control tumors using a high field magnet (11.7 Tesla). 
Furthermore, tumor xenografts extracted at 10 days 
after inoculation showed LRP gene expression (Figure 
10)  [34].  These  results  show  that  CEST  imaging  to 
detect gene expressions by MR, but energy deposition 
in tissue (specific absorption rate : SAR) and the mil-
limolar  sensitivity  of  the  technique  are  limitations 
[35]. SAR could be described as the rate at which en-
ergy is absorbed by the body when exposed to a ra-
diofrequency electromagnetic field, which is sufficient 
to  cause  tissue  heating.  Furthermore,  SAR  is  de-
pendent  on  magnetic  field  strength,  which  implies 
that  the  ultra-high  magnet  field  needed  for  CEST 
signal  detection  is  likely  to  cause  significant  tissue 
heating [36]. Further studies are required to validate 
the applicability of CEST-MRI in a clinical setting. 
 
 
 
Figure  8. TEM images of magA-transduced cells. Nanoparticles were observed enclosed within membranevesicles. These vesicles, 
resembling endosomes, were found individually (A) or in groups (B), with varying numbers of particles (B, D), whereas in uninduced cells 
(E) no particles were observed. (B) The Arrows show compartmentalization resembling the multivesicular bodies observed during cellular 
degradation. (C) Particles can also be seen outside the vesicles. [Reprinted from ref. 33 with permission]. Theranostics 2012, 2(4) 
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Figure 9. MRI of magA cell induction in vivo. (A) T2*-weighted image of mouse brain with transplanted magA cells (right, white arrow) 
and GFP control cells (left). These cells were not induced or incubated with iron supplement prior to transplantation. MagA cells exhibited 
significantly lower MR signals, reflecting an increase in R2, and suggesting that magA cells are able to use endogenous iron sources. The 
control cells on the left do not show this effect. (B) MR image of the same mouse brain showing that magA cells are readily seen by T2WI, 
which is less sensitive than T2* for magnetic nanoparticles. Fluorescence histology confirmed the presence of control (green) and 
magA-positive (red) cells. Magnified green and red channels are also shown. (C) Brightfield histology section of the brain, indicating the site 
of transplanted cells. [Reprinted from ref. 33 with permission]. 
 
 
 
 
Figure 10. Chemical-Exchange Saturation Transfer. (A) Frequency-selective radiofrequency pulses label amide protons (green). These 
protons exchange with water protons (curved arrow), and thus, reduce MR signal intensity (ΔSI). (B) RT-PCR result of xenografts. (C) MR 
images. (D) A CEST signal intensity-difference map overlaid on anatomical images of LRP-expressing (left) and control (right) xeno-
graft-containing brain. [Reprinted from ref. 34 with permission]. 
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Conclusion and future perspectives 
Progress toward the development of a good MR 
reporter continues to be made. MRI continues to lag 
behind  other  molecular  imaging  modalities  in  this 
field because of its intrinsic sensitivity and the associ-
ated necessity of high-field magnet for signal detec-
tion, because of immunologic and biologic issues, or 
simply  because  it  does  not  provide  an  instant 
„hot-spot‟  signal  like  PET  or  bioluminescence.  Until 
recently, no report on therapeutic gene delivery me-
diated  by  a  solitary  imaging-and-suicide  reporter, 
such as HSV1-sr39tK for PET imaging, had been re-
ported for MRI [37, 38]. But researchers have showed 
that  MR  reporter  gene  may  provide  tumor-specific 
cytoxicity, for example, by cytosine deaminase and its 
metabolite 5-FU. Some approaches alleviate the need 
for external contrast injection, such as ferritin-related 
MRI,  implicating  its  application  in  brain  with 
blood-brain barrier [39]. MR is indeed slowly gaining 
its  foothold  in  the  field  of  reporter  gene  imaging. 
There is no single imaging molecular imaging modal-
ity that will meet every purpose. Fusion reporters and 
fusion imaging modalities will probably be devised to 
take  advantage  of  the  three-dimensional  microana-
tomical imaging offered by MRI, and the combined 
biologic  and  chemical  efforts  being  made  will  un-
doubtedly  accelerate  the  application  of  molecular 
genetic MRI. 
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